Antipsychotics Worsening Catatonia in an Underlying Psychotic Disorder
His catatonia responded well to lorazepam, but the psychotic disorder underneath it is still fully active. Restarting an antipsychotic risks the exact symptom that just resolved, in a genuinely underrecognized way.
F.H., a 30-year-old man, was working toward a certification in HVAC repair when his illness first emerged two years ago, and has returned to that same training program twice since, each time interrupted by a relapse, something his instructor has been unusually patient about according to F.H.'s case manager. He has a two-year history of schizophrenia and developed catatonic stupor three weeks ago during a psychotic relapse, responding well to a lorazepam challenge and continued benzodiazepine treatment, with catatonic symptoms now fully resolved.
His underlying psychosis, however, is still clearly active — ongoing paranoid delusions and disorganized speech that predate the catatonic episode and have not improved with benzodiazepine treatment alone, since lorazepam addresses catatonia specifically rather than the psychotic disorder driving it. F.H. himself says he wants to get back to the training program a third time and is anxious about how much longer that might take.
This creates a real and underrecognized tension: antipsychotics, particularly high-potency D2 antagonists, can in some patients worsen or precipitate catatonic symptoms, a risk not widely appreciated outside specialist literature and easy to overlook once catatonia has resolved and attention shifts back to the psychosis that still needs treatment. F.H. genuinely needs antipsychotic treatment for his underlying illness — benzodiazepines are not an adequate treatment for his ongoing delusions and disorganization — but restarting one carries a real, specific risk of re-triggering the exact symptom that has just been brought under control, a risk that has nothing to do with whether the antipsychotic itself was previously well tolerated by him.
Restarting an antipsychotic, and how
He needs an antipsychotic — benzodiazepines alone aren't treating his active delusions, and leaving that untreated has its own real cost. He tolerated risperidone before this episode without any catatonic symptoms — that's real data about him specifically, not just a population risk. I'd restart at a low dose and watch closely, rather than avoid antipsychotics altogether out of a risk that, in his case, hasn't actually manifested.
His prior tolerance is real, but I don't think it tells us what you're using it to tell us. That trial predates this catatonic episode — it shows risperidone didn't trigger catatonia in a patient who wasn't yet catatonia-prone, not that it's safe in one who now is. Redon and colleagues' 2025 systematic review in European Psychiatry, pooling data across dozens of published cases, found the risk specifically concentrated in agents with higher D2 receptor affinity — not a theoretical caution, a real, mechanism-consistent pattern. I'd choose the specific drug carefully, not just default to what worked before: a partial-agonist option is the more cautious starting point, and case reports in the same literature describe that particular mechanism actually resolving catatonic symptoms in some patients rather than provoking them.
I'd also keep the lorazepam running in parallel through the restart, not stopped the moment catatonia resolved — it gives us a real safety margin if antipsychotic-related catatonic symptoms start to re-emerge before we'd otherwise notice.
Whichever of you turns out to be right about drug choice, the thing that actually catches this early is structure, not judgment calls made once. The catatonia rating scale needs to be rechecked on a defined schedule through the antipsychotic restart, not just monitored informally — this is exactly the kind of risk that gets missed once everyone's attention has shifted back to the psychosis, regardless of which agent turns out to carry the risk in his specific case.
Agreed: restart aripiprazole at a low dose, continue lorazepam in parallel with a defined taper schedule, and repeat the catatonia rating scale twice weekly through the transition rather than relying on informal observation.
The team named the risk explicitly to F.H. himself: the goal is treating both problems without one treatment quietly re-triggering the other, and he was asked to report any return of stiffness, mutism, or immobility immediately rather than waiting for the next scheduled check.